Overview – Advanced Anti-Cancer Targeted Therapy
Bevacizumab Biosimilar Injection (100mg / 400mg) is a clinically established anti-VEGF monoclonal antibody therapy designed for modern oncology treatment protocols.
It is widely used in targeted cancer treatment regimens, especially for tumors that require suppression of blood vessel growth to slow disease progression.
This biosimilar is developed to match reference biologics in efficacy, safety, and quality performance, while offering a cost-effective alternative for global healthcare systems.
🧪 Mechanism of Action – How Bevacizumab Works in Cancer Treatment
Bevacizumab acts by targeting VEGF (Vascular Endothelial Growth Factor), a key protein responsible for tumor angiogenesis.
🔬 Therapeutic Action:
- Blocks blood supply formation to tumors
- Reduces tumor growth and metastasis potential
- Enhances effectiveness of chemotherapy combinations
- Improves disease management outcomes in advanced cancers
💉 Available Strengths for Hospital Use
- Bevacizumab Biosimilar 100mg Injection
- Bevacizumab Biosimilar 400mg Injection
Both strengths are used based on oncology dosing protocols, patient body weight, and cancer stage severity.
🏥 Treatment Applications (Oncology Indications)
Bevacizumab biosimilar is integrated into treatment plans for multiple cancer types:
🎗️ Approved & Common Uses:
- Metastatic colorectal cancer
- Non-small cell lung cancer (NSCLC)
- Ovarian epithelial cancer
- Cervical cancer (advanced stage)
- Renal cell carcinoma
- Glioblastoma multiforme
🌐 Global Export Market Coverage
We support international oncology drug distribution networks with regulated supply and logistics support.
🚚 Fast Delivery Regions:
🌍 Africa
🇰🇪 Kenya | 🇳🇬 Nigeria | 🇬🇭 Ghana | 🇿🇦 South Africa
🌏 Asia
🇵🇭 Philippines | 🇻🇳 Vietnam | 🇦🇪 UAE | 🇸🇦 Saudi Arabia | 🇺🇿 Uzbekistan | 🇰🇿 Kazakhstan
🌎 Western Countries
🇺🇸 USA | 🇬🇧 UK
🏭 Why Choose Indian Biosimilar Manufacturing?
India is a global leader in affordable oncology biologics and biosimilars export.
✔ Key Advantages:
- WHO-GMP & ISO certified production standards
- Cost-effective oncology treatment solutions
- High batch consistency & quality control
- Regulatory export documentation support
- Cold-chain logistics for biologics stability
- Reliable bulk hospital supply capability
🧬 Role in Modern Oncology Protocols
Bevacizumab is commonly used in combination therapy regimens, including:
- Chemotherapy + anti-VEGF therapy
- Maintenance therapy in metastatic cancers
- Advanced-stage tumor suppression protocols
- Palliative oncology care support
This makes it a critical molecule in precision oncology treatment strategies.
🚚 Export & Supply Capability
Cordium Pharmaceuticals Pvt Ltd provides:
- Bulk oncology drug export supply
- Hospital tender & institutional procurement support
- Distributor partnership programs
- Cold-chain packaging & global air cargo shipping
- COA, MSDS, and regulatory export documentation
📦 Ideal For
- Hospitals & oncology departments
- Cancer treatment centers
- Pharmaceutical distributors
- Government healthcare procurement
- International medical importers
🏁 Conclusion
Bevacizumab Biosimilar 100mg / 400mg Injection represents a critical advancement in targeted oncology treatment, offering globally accepted clinical benefits with improved affordability.
With strong manufacturing standards and global logistics capability, India continues to lead biosimilar exports for life-saving therapies.
Cordium Pharmaceuticals Pvt Ltd ensures consistent quality, regulatory compliance, and fast international delivery across Africa, Asia, the Middle East, Europe, and North America.
